Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Targets in High-Risk Patients. The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) Trial

Journal of the American College of Cardiology

Volumn 52, Issue 8, 2008, Pages 626-632

  Ballantyne, Christie M ^a   Raichlen, Joel S ^b   Cain, Valerie A ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

apolipoprotein B; high risk patients; low density lipoprotein cholesterol; non high density lipoprotein cholesterol; statins

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; TREATMENT RESPONSE; VASCULAR DISEASE;

AGED; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETIC ANGIOPATHIES; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LINEAR MODELS; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SIMVASTATIN; SULFONAMIDES;

EID: 48849112223     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.04.052     Document Type: Article

References (23)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 106 (2002) 3143-3421
2. Barter P.J., Ballantyne C.M., Carmena R., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 (2006) 247-258
3. Walldius G., and Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 255 (2004) 188-205
4. Lamarche B., Moorjani S., Lupien P.J., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation 94 (1996) 273-278
5. Westerveld H.T., Roeters van Lennep J.E., Roeters van Lennep H.W.O., et al. Apolipoprotein B and coronary artery disease in women. A cross-sectional study in women undergoing their first coronary angiography. Arterioscler Thromb Vasc Biol 18 (1998) 1101-1107
6. Durrington P.N. Can measurement of apolipoprotein B replace the lipid profile in the follow-up of patients with lipoprotein disorders?. Clin Chem 48 (2002) 401-402
7. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106 (2002) 2526-2529
8. Miremadi S., Sniderman A., and Frohlich J. Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?. Clin Chem 48 (2002) 484-488
9. Hirsch G.A., and Blumenthal R.S. Usefulness of non-high-density lipoprotein cholesterol determinations in the diagnosis and treatment of dyslipidemia. Am J Cardiol 91 (2003) 827-830
10. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 (2003) 777-780
11. Pischon T., Girman C.J., Sacks F.M., Rifai N., Stampfer M.J., and Rimm E.B. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112 (2005) 3375-3383
12. Leroux G., Lemieux I., Lamarche B., et al. Influence of triglyceride concentration on the relationship between lipoprotein cholesterol and apolipoprotein B and A-I levels. Metabolism 49 (2000) 53-61
13. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
14. Ridker P.M., Rifai N., Cook N.R., Bradwin G., and Buring J.E. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294 (2005) 326-333
15. Gotto Jr. A.M., Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
16. Simes R.J., Marschner I.C., Hunt D., et al., LIPID Study Investigators. Relationship between lipid levels and clinical outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) trial. Circulation 105 (2002) 1162-1169
17. Bachorik P.S., Lovejoy K.L., Carroll M.D., and Johnson C.L. Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 43 (1997) 2364-2378
18. Brunzell J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51 (2008) 1512-1524
19. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H., Shear C., and ACCESS Study Group. Atorvastatin Comparative Cholesterol Efficacy and Safety Study. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 88 (2001) 265-269
20. Ballantyne C.M., Bertolami M., Garcia H.R.H., et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: MERCURY II. Am Heart J 151 (2006) 975.e1-975.e9
21. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
22. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol 47 (2006) 2130-2139
23. Vaughan C.J., and Gotto A.M. Update on statins: 2003. Circulation 110 (2004) 886-892